Two NGOs have challenged the patent protection of a leukaemia drug produced by Swiss pharmaceutical company Novartis. They complain that the patent on the drug Kymriah allows Novartis to charge inflated prices for its use on patients.
This content was published on
1 minute
swissinfo.ch/mga
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions.
The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have not responded to previous therapies, costs CHF370,000 ($375,000) per infusion. This makes it the most expensive drug in Switzerland, say the NGOs.
If the NGOs succeed in nullifying the patent, Novartis will still be able to sell the drug but without having a monopoly that allows it to charge more.
The decisions of the Munich patent authority are binding on Switzerland despite not being a member state of the European Union. Novartis told the Swiss news agency Keystone-SDA that its lawyers are analysing the legal challenge.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
Compensation for Syrian after pregnant wife denied help on Swiss train
This content was published on
Switzerland’s Federal Court has partially upheld the appeal of a Syrian family being deported from Switzerland to Italy in 2014. The man now also receives compensation.
Swiss-EU negotiations: Cassis to meet Sefcovic in Bern
This content was published on
Swiss Foreign Minister Ignazio Cassis will meet the Vice-President of the EU Commission, Maros Sefcovic, in Bern on Wednesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss healthcare costs expected to rise well above inflation
This content was published on
On Monday, SantésuisseExternal link outlined the main reasons for the expected increases in health insurance policies. It predicts a 6% rise in physiotherapy treatments, the same greater demand for care for the elderly and in nursing homes and 5% extra medical diagnostics being performed in laboratories. In addition, insurers expect costs to rise to a…
Generic drugs remain twice as expensive in Switzerland
This content was published on
Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
WHO adopts watered-down resolution on drug transparency
This content was published on
The World Health Organization (WHO) has adopted a resolution to improve transparency on drug prices but some people say it doesn't go far enough.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.